Social network data of tuberculosis (TB) patients could explain the source and pattern of disease spread. A review of the published literature highlights that social network data could identify hidden social or epidemiological links among TB patients and improved TB case finding.

One of the first multicenter randomized trials was the British Medical Research Council (MRC) streptomycin trial. From the first meeting of the special committee to “plan trials of streptomycin in tuberculosis” in September, 1946, the primary trial results from 107 participants followed for 12 months were published in the British Medical Journal two years later in October, 1948. Although treatment with a single drug was subsequently shown to be inadequate because of the generation of drug resistance, the results of the trial changed clinical practice.

The objective of the study was to review policies on management of latent tuberculosis infection in countries with low and high burdens of tuberculosis.

Original Source

Of patients with multidrug-resistant tuberculosis (MDR TB), <50% complete treatment. Most treatment failures for patients with MDR TB are due to death during TB treatment. We sought to determine the proportion of deaths during MDR TB treatment attributable to TB itself. We used a structured verbal autopsy tool to interview family members of patients who died during MDR TB treatment in India during January–December 2016.

The existing treatment regime against tuberculosis is not adequate, and novel therapeutic interventions are required to target Mycobacterium tuberculosis (Mtb) pathogenesis. We report Pranlukast (PRK) as a novel allosteric inhibitor of Mtb's arginine biosynthetic enzyme, Ornithine acetyltransferase (MtArgJ). PRK treatment remarkably abates the survival of free as well as macrophage‐internalized Mtb, and shows enhanced efficacy in combination with standard‐of‐care drugs.

The risk of tuberculosis outbreaks among people fleeing hardship for refuge in Europe is heightened. We describe the cross-border European response to an outbreak of multidrug-resistant tuberculosis among patients from the Horn of Africa and Sudan.

Original Source

An understanding of the trends in tuberculosis incidence, prevalence, and mortality is crucial to tracking of the success of tuberculosis control programmes and identification of remaining challenges. We assessed trends in the fatal and non-fatal burden of tuberculosis over the past 25 years for 195 countries and territories.

Original Source

TB remains a big killer despite the development of a better test for detecting the disease.

Original Source

Recent in vitro and animal studies have found the proton pump inhibitor (PPI) lansoprazole to be highly active against Mycobacterium tuberculosis. Omeprazole and pantoprazole have no activity. There is no evidence that, in clinical practice, lansoprazole can treat or prevent incident tuberculosis (TB) disease.

Original Source

The WHO Global Ministerial Conference “Ending TB in the Sustainable Development Era: A Multisectoral Response” aims to accelerate implementation of the WHO End TB Strategy - with immediate action addressing gaps in access to care and the MDR-TB crisis - in order to reach the End TB targets set by the World Health Assembly and the United Nations

Pages